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Abstract 
Natural products have been a rich source of compounds for drug discovery. However, their use has 
diminished in the past two decades in part because of technical barriers to screening natural 
products in high-throughput assays against molecular targets. Here, we review advances in chemical 
techniques for the isolation and structural elucidation of natural products that have reduced these 
technological barriers. We also assess the use of genomic and metabolomic approaches to augment 
traditional methods of studying natural products, and highlight recent examples of natural products 
in antimicrobial drug discovery and as inhibitors of protein ?protein interactions. The growing 
appreciation of functional assays and phenotypic screens may further contribute to a revival of 
interest in natural products for drug discovery. 
 
Introduction 
There is an increasingly powerful case for revisiting natural products for drug discovery. Historically, 
natural products from plants and animals were the source of virtually all medicinal preparations, and 
more recently, natural products have continued to enter clinical trials or to provide leads for 
compounds that have entered clinical trials, particularly as anticancer and antimicrobial agents
1-3
. A 
detailed analysis of new medicines approved by the US Food and Drug Administration between 1981 
and 2010
4
 revealed that 34% of those medicines that were based on small molecules were natural 
products or direct derivatives of natural products, including the statins, tubulin-binding anticancer 
drugs and immunosuppressants
5-8
.
 
This contribution of natural products seems impressive, especially against a backdrop of the 
diminished focus on natural products by the major pharmaceutical companies. There have been 
several reasons for the lack of enthusiasm for using natural products for drug discovery in industry. 
There are legitimate concerns arising from the United Nations Convention on Biological Diversity 
that seeks to regulate international access to natural products, but these can be dealt with by 
following accepted best practices (Box 1). Of greater concern was the belief that natural products 
are somehow incompatible with drug discovery approaches based on high-throughput screening 
(HTS) directed at molecular targets
9
, and concerns about the difficulties associated with the 
repeated isolation of known compounds and with synthesizing natural products during 
pharmaceutical manufacture
10
. This was coupled with the as yet unfulfilled expectation that 
combinatorial chemistry techniques could provide all the chemicals needed for successful lead 
discovery
4,11, 12
. Many large screening collections have disappointed in practice, and it is recognized 
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that diversity within biologically ƌĞůĞǀĂŶƚ ‘ĐŚĞŵŝĐĂůƐƉĂĐĞ ? is more important than library size. A 
ƌĞƚƌŽƐƉĞĐƚŝǀĞĂŶĂůǇƐŝƐŽĨŽŶĞĐŽŵƉĂŶǇ ?Ɛ,d^ĐĂŵƉĂŝŐŶƐŝŶĚŝĐĂƚĞĚƚŚĂƚƐĞůĞĐƚŝŽŶŽĨƉůĂƚĞƐĐŽŶƚĂŝŶŝŶŐ
natural products would have significantly improved hit rates
11
. To a certain extent, compound 
libraries are being designed to mimic more closely the chemical properties of natural products,
10,
 
13-
17 
although natural products themselves are generally overlooked. 
Natural product collections exhibit a wide range of pharmacophores and a high degree of 
stereochemistry and these properties are expected to contribute to the ability of such collections to 
provide hits  ?  even against the more difficult screening targets, such as protein ?protein 
interactions
10
. However, natural products may have the additional advantage over synthetic 
compounds of being natural metabolites: compounds that are successful as drugs have been 
suggested to ŚĂǀĞƚŚĞƉƌŽƉĞƌƚǇŽĨ ‘metabolite-ůŝŬĞŶĞƐƐ ?18. This means that such compounds are not 
only biologically active, but also likely to be substrates for one or more of the many transporter 
systems that can deliver the compounds to their intracellular site of action.  
A high degree of bioavailability could be particularly important if the trend towards more 
functional assays continues. With the development of high-content screening and other phenotypic 
assays that use cells or model organisms
19, 20
, test-compound bioavailability becomes important 
earlier in the screening cascade than if the primary assay is a molecular one, such as an isolated 
protein assay. There is also increasing interest in the clues from traditional uses of plant extracts  ?  
for example, those in Chinese traditional medicine  ?  to guide new drug discovery. There are several 
examples of drugs that are based on Chinese traditional medicine
21-23
, although it is still unclear 
whether or not these are useful signposts
24
. 
Given the recent technological advances, and the apparently growing appreciation of 
functional assays and phenotypic screens, will natural products come back into favour among drug 
discovery scientists? In this Review, we describe recent efforts to optimize the use of natural 
products and their derivatives in drug discovery. We first discuss advances in the development of 
screening libraries based on natural product extracts, fractions prepared from extracts and purified 
compounds, and the use of chemical scaffolds based on natural products. We then consider the use 
of metabolomics and metagenomics in identifying new classes of natural products, such as those 
from previously non-cultivated bacterial strains. Finally, we review the progress in the discovery of 
potential drugs derived from natural products, in particular citing examples of products with novel 
antimicrobial properties and products that target protein ?protein interactions. 
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Advances in natural product-based screening 
The traditional approach of bioassay-guided isolation of natural products is being modified to take 
advantage of technological advances, to accommodate current understanding in medicinal 
chemistry, and to explore biologically relevant chemical space via cheminformatic approaches to the 
design of libraries.  
Advances in natural product-based screening collections. Traditionally in natural-product research, 
concentrated extract samples were screened in bioassays
25
. Such extracts are complicated mixtures. 
All of the components of the extract may reach the biological target in the assay, but some 
components may be in concentrations too low to have measurable effects, or the signal from the 
assay may be confounded by interference or nuisance compounds, or by the additive or synergistic 
effects of several compounds. Isolating each compound from a crude extract in advance of 
screening, however, is likely to be too onerous and uneconomical to be feasible for large numbers of 
samples.  
A first step towards simplifying extracts and making them more suitable for use in bioassays 
is to remove compounds that are likely to cause artefacts: polyphenolic tannins are the usual 
suspects in plant extracts
26
. Then, fractions of reduced complexity can be prepared for screening, 
allowing the scale to be miniaturized and the speed enhanced. One necessity arising from 
pre-fractionation is that of a repository, from which small quantities of an increased number of 
fractions can be biologically tested using HTS. The use of simplified fractions, together with sensitive 
nuclear magnetic resonance (NMR) techniques, has solved the isolation and structure-elucidation 
bottleneck. Additionally, as fractions are prepared by a chromatographic method, subsequent 
chromatography on existing fractions is more likely to be achievable, avoiding the previous danger of 
not finding the responsible constituent in active crude extracts.  
Numerous pre-fractionation strategies have been reported
27-36
, and these are summarized in 
Table 1. Pre-fractionation HTS strategies have been shown to give higher hit rates. Of a microbial 
natural-product library comprising 1,882 active cultures, 80% of the activities that were found by 
nine HTS campaigns (against three ion channels, three kinases and three unspecified screens) was 
observed only in the fractions, whereas in the crude extract only 12.5% of the activity was found. 
Only 7.6% was observed in both the crude extract and the fractions
29
. A very similar result was 
achieved using the simpler four fractions per extract approach. Of the 1,700 active fractions from 
eleven HTS screens (including whole cell and enzyme/protein based assays), 80% of the primary-
 5 
 
screen hits from pre-fractionated samples was not observed in assays of the associated crude 
extract
28
. 
 
Screening libraries based on natural products. A challenge in medicinal chemistry is the 
identification of molecules that are complementary to the surface of a macromolecular target 
involved in disease pathology. Biological structural space has been defined as the protein-binding 
sites of potential ligands
37
. The question of how biologically relevant the diversity in chemical 
libraries is remains a critical problem for medicinal chemists despite the use of high-throughput 
technologies
37
. 
The majority of screening libraries that are based on synthetic compounds are comprised of 
compounds that have drug-like or lead-like properties with regard to drug metabolism and 
pharmacokinetics (DMPK) qualities
38
, with compounds that have reactive groups or other 
problematic chemical substructures removed
39
. This results in a subset of chemical diversity that is 
aimed towards cell permeability and oral bioavailability, but which still does not address the 
question of biologically relevant chemical space. As a result, the screening of large numbers of 
compounds is still necessary to identify active compounds. The reverse approach is to start with a 
set of biologically relevant chemicals and then to apply drug-like or lead-like absorption, distribution, 
metabolism, excretion and toxicity (ADMET) filters. Natural products have a distinct advantage in 
this approach, as they inherently fall in regions of biologically relevant chemical space
13, 40-42
 (Fig. 1).  
The modern drug-discovery approach of pre-filtering screening libraries for drug- or lead-
likeness can be applied to natural-product fraction libraries. In this regard, the Wyeth fractionation 
procedure recognized the value in collecting fractions that were most likely to contain compounds 
with drug-like properties, and so the highly polar compounds, the early-fractionation material 
consisting of media components, and the late-eluting lipophilic portion were discarded
29
. Natural 
product samples can be enriched for drug-like properties by concentrating on fractions that contain 
compounds in the appropriate range of lipophilicity
33
. The closer a fraction library can approach the 
typical industry definition of a lead molecule with regards to physicochemical properties, the more 
likely the success in identifying a starting point that is attractive from a medicinal chemistry 
perspective. In order to align natural-product screening with the same physicochemical profile of 
synthetic screening libraries, a solid-phase extraction (SPE) method to remove high LogP 
components and provide LogP < 5 constituents with the required physicochemical profile prior to 
fractionation may be used
38, 48
.  
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Natural products interrogate a different, wider and more drug-like chemical space than do 
synthetic derivatives
43, 44
. Furthermore, it has been shown that 83% of core ring scaffolds that are 
present in natural products were absent from commercially available molecules and screening 
libraries
18
. It was concluded that including molecules with a natural-product-like scaffold into the 
screening library would increase hit rates
18
.  
Besides natural-product-likeness based on chemical structure, similarity measures can also 
be based on physicochemical properties
16
. The chemical space navigation tool ChemGPS-NP was 
used to analyse natural products and bioactive medicinal chemistry compounds in the WOMBAT 
database
16
. The overlap between the biologically relevant chemical space that was covered by 
natural products and the biologically relevant chemical space that was covered by medicinal 
chemistry compounds, was limited, showing that natural products cover parts of chemical space that 
lack representation by medicinal chemistry compounds. Such natural products may be useful novel 
leads
16
. A comparison of the Euclidean distances (EDs) in chemical space between approved drugs 
included in the GVK BIO drug database and natural products from the Dictionary of Natural Products 
identified many drug ?natural-product pairs. This analysis revealed that 99.5% of all drugs have a 
natural-product  ‘neighbour ? that is closer than ED = 10, and that 85% of drugs have a natural-
product neighbour closer than ED = 1, where ED = 0 is an exact match. This analysis indicated that 
natural products with very short EDs to any approved drug may be a potential lead against the same 
target as that of the drug
16
. These property-based similarity calculations can identify structurally 
dissimilar compounds that have neighbours with similar properties
16
.  
Another strategy towards creating a library based on natural products relies on a structure-
based approach to identify biologically relevant compound classes and scaffolds
13
. Biology-oriented 
synthesis (BIOS) follows the principle that over the course of evolution, nature conserves the 
scaffolds of natural products and of protein backbones. In BIOS, compound classes and scaffolds are 
therefore selected primarily on the basis of biological compatibility. The particular compound class is 
decided by either Structural Classification of Natural Products (SCONP) or Protein Structure Similarity 
Clustering (PSSC), or both used in combination. This approach has led to  ‘natural-product-derived ? 
(where the scaffold is identical to the natural-product scaffold) and  ‘natural-product-inspired ? 
(where the scaffold is closely related to natural-product scaffold) libraries. Natural-product-inspired 
compound collections that have been synthesized according to the logic of BIOS have proven to be 
enriched in bioactivity over typical collections of synthetic compounds: hit rates of 0.2 ?1.5% have 
been found against molecular targets such as phosphatases and in cell-based assays
13
. For example, 
combined PSSC and SCONP were used to generate a library of 483 decalins to discover selective 
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ŝŶŚŝďŝƚŽƌƐŽĨĐŽƌƚŝĐŽƐƚĞƌŽŝĚ ? ?ɴ-dehydrogenase isozyme 1 (11ɴHSD1). PSSC identified similarities 
between the M-phase inducer phosphatase 1 CDC25A, acetylcholinesterase and 11ɴHSD1. 
Subsequently, the CDC25A inhibitor dysidiolide and the 11ɴHSD1 ligand glycyrrhetinic acid were 
analysed using SCONP to identify a 1,2-dehydrodecalin scaffold as the basis for compound synthesis. 
This scaffold was the basis of synthesis to generate a library that contained three highly isoenzyme-
selective 11ɴHSD1 inhibitors with nanomolar potency13.  
The use of natural products as a guiding structure, and the chemical transformation of 
scaffolds derived from (embedded within) the guiding structure to create natural-product-like 
libraries, has been analysed with respect to variation of the two main lead-like descriptors: 
molecular weight (MW) and lipophilicity (logP)
45
. This analysis revealed that, although there are 
many strategies to create natural-product-like libraries, the impact of chemical transformations on 
physicochemical properties in the generation of libraries has not been uniformly addressed. During 
the lead-optimization process an increase in MW and logP is generally observed
46, 47
, and thus the 
optimum property cut-off values when identifying natural product lead-like libraries should respect 
the conditions MW < 350 Da and  ?1 < logP < 3. If library generation is to fit within the modern drug 
discovery paradigm, the library members should all be within biologically relevant chemical space 
and allow for increases in MW and logP during lead-optimization: that is, the library members must 
be within the orange square of Figure 1. If the guiding natural product falls in the lead-like region, 
the guiding natural product can be used as a starting point for the preparation of a library with 
skeletal and stereochemical variations, provided the generated molecules remain in the lead-like 
region
45
. However, if the guiding natural product has a MW > 350 Da, it is necessary to reduce the 
structural complexity
48
  and if the guiding natural product has a MW < 350 and logP > 3, it is 
necessary to reduce lipophilicity.  
The structures of many natural products are available in searchable databases (discussed in 
Table 2) and some of these have been used in virtual-screening campaigns. These approaches can 
help optimize the use of compounds that are available in only very small amounts
49
. 
 
Applying  ?ŽŵŝĐƐ ?ƚŽŶĂƚƵƌĂůƉƌŽĚƵĐƚƐ 
Metabolomics arose from the concepts of metabolic profiling and has the goal of qualitatively and 
quantitatively analysing all the metabolites that are contained in an organism at a specific time and 
under specific conditions. This approach ultimately allows indirect monitoring of gene function and 
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the biochemical status of an organism. A combination of metabolomics and genomics can be used to 
optimize a biosynthetic pathway to selectively produce biologically active secondary metabolites
50-52
.  
Profiling and isolation using metabolomics. The application of metabolomics in natural product 
research began almost a decade after it was already well established in the fields of biomedical
53
 and 
agricultural research
54
  with the introduction of photo-diode arrays
55
 along with HRFTMS
56
 (high-
resolution Fourier-transform mass spectrometry) detectors that were coupled with high-
performance liquid chromatography (HPLC). By the beginning of the millennium, high-throughput 
sequencing was emerging and there was a shift from pure genetic research to the elucidation of 
gene function and expression
57, 58
. The ability of an organism to produce secondary metabolites is a 
phenotype and these metabolic phenotypes have been researched using metabolomics (which, in 
such cases, may also be known as phenomics)
59, 60
.  
The basic analytical techniques HRFTMS
61, 62
 and NMR spectroscopy
63-66
 are being used to 
dereplicate and quantify known metabolites against novel natural products
67, 68
 (Box 2). 
Dereplication is a massive job
69, 70
 because secondary metabolites have diverse atomic 
arrangements, resulting in variations in chemical and physical properties. A combination of analytical 
methods that includes ultra-violet, tandem mass spectrometry, and NMR spectral data must be used 
to ensure the correctness of the identification of the basic structure of dereplicated compounds in 
crude samples. The UV data set is limited in the analysis and dereplication of chromophore-
containing metabolites; whereas in mass spectrometry, there is the risk of missing poorly ionizing 
compounds that are only detectable in one mode. For example, phenolic and anthraquinone 
compounds poorly ionize in the positive mode but ionize very well in the negative mode
68
, whereas 
the opposite can be said for alkaloids. Secondary metabolites can also be found in a wide range of 
concentrations. Reliable, robust, selective and high-resolution analytical methods are therefore 
required for identifying and quantifying the multiple chemical groups of natural products. Standard 
NMR methods or pulse sequences are being reconceived to identify a complex mixture of 
metabolites in a typical natural-product extract. One method of doing this is two-dimensional 
J-resolved NMR 
71,72
 (Box 2).  
Along with metabolomics-guided fractionation tools, it is possible to pinpoint active components at 
the first fractionation step, as well as predict which functional structures might be bioactive
68, 73
. The 
use of metabolomics could help prioritise fractions for further purification, which should save time 
and resources in isolating the target compounds (Fig. 2).There is rapid progress on pioneering 
information technology
67, 74-77
 for quick and efficient analysis of large data sets of natural product 
libraries 
78
. These harness innovative approaches to analyse mass spectrometry data   ?  for example, 
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MZmatch
79-81
 and XCMS
82, 83
  ?  that can be used with differential expression analysis and with online 
databases (such as ChemSpider, MarinLit and the Dictionary of Natural Products) or in-house 
databases
50
. Differential expression analysis
79
 involves a series of processes including nonlinear 
retention time alignment of compounds that are unique to the sample, followed by matched 
filtration of authentic peaks in mass spectra to the sample and against the noise and background 
peaks (such as those resulting from solvents or media). Finally, peaks are detected and known 
metabolites are matched to  compounds using a database such as the Dictionary of Natural Products 
. Unique features of compounds can be deduced to forecast biological activity through pattern 
recognition. Multivariate analysis using statistical tools such as unsupervised principal components 
analysis, supervised discriminant function analysis and Z-score analysis can be used for pattern 
recognition programmes which may predict the biological activity that results from particular 
features of compounds
67, 73, 77, 84, 85
. 
Metabolomics can also be applied to optimize fermentation, and to detect and maintain the 
production of interesting secondary metabolites during cultivation and production processes, hence 
assisting in enhancing biosynthesis of desired compounds. Along with the OSMaC (One-Strain ?
Many-Compounds) approach
86, 87
, metabolomics can be used to explore and statistically validate 
relationships between culture methods, diversity, bioactivity, and metabolome evolution in a 
microbial isolate
56, 68
. During scale-up, production processes in a small-scale fermenter can be 
optimized using real-time metabolomics
88, 89
. A detailed real-time metabolome-pathway analysis can 
fully characterize the intermediates, by-products and degradants within a metabolic flux system
90
. 
Thus, metabolic bio-production systems can be engineered; for instance, the stability of the 
production of the desired components when changing certain fermentation parameters can be 
checked and maintained
90
.  
Traditional herbal medicine  ?  for instance traditional Chinese medicine (TCM)  ?  entails the 
use of a mixture of plant products. Metabolomics has facilitated the study of the effects of these 
complex mixtures on a parallel complex biological system
21, 91-93
. Metabolic-profiling strategies also 
have practical uses in research and development and in the quality control of raw- and end-product 
TCM products
94
. Analysis of tea-sourced
95
 health products and Chinese patent medicine samples has 
used chemometric-guided HPLC
95-97
 to provide quantitative information on specific individual 
compounds from within overlapping profiles of co-eluting compounds. This metabolomics approach 
of metabolic fingerprinting, coupled with chemometric analysis, has been described in the analysis 
of TCM products and of raw materials from Angelica sinensis
98, 99
. Metabolic profiling with 
electrospray ionization quadrupole time-of-flight mass spectrometry (ESI ?TOFMS), another 
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metabolomics-based analytical method, was also used for the efficient isolation of a new antitumour 
saponin from Panax ginseng, a popular TCM
100
. 
Metabolomics data can be mined to postulate biosynthetic precursors which can be useful in 
engineering pathways to increase the yield of the functional natural product. For example, in the 
production of ephedrine bronchodilators, targeted metabolic profiling and comparative biochemical 
analyses revealed benzaldehyde to be an important precursor of phenylpropylamino alkaloids 
produced in Ephedra spp
101
. Moreover, through metabolic profiling it was possible to investigate the 
biosynthesis of tanshinone and to increase expression of one of the tanshinone-synthesizing 
enzymes SmCPS (Salvia miltiorrhiza copalyl diphosphate synthase) in S. miltiorrhiza hairy root 
cultures, thereby increasing overall tanshinone production
102
. Tanshinones have shown promise as 
therapeutic agents for oxidative stress injury in neurodegenerative, cardiovascular
103
 and 
cerebrovascular disorders
104
. For instance, tanshinones have been found to delay the development 
of myocardial infarction-induced ischaemia in rats, by decreasing infarct size and improving systolic 
function
103
. In zebrafish- and rodent-models of seizures, tanshinones  ? in particular, one of the 
active tanshinones, tanshinone IIA  ?  were shown to suppress seizure activity104. Tanshinone IIA is 
already prescribed in China to treat cerebral ischaemia.  
Metagenomics or gene manipulation for synthetic pathways. Genomics and metagenomics have 
become part of the workflow (Fig. 2) in the target-directed search not only for new bioactive 
secondary metabolites
51, 105-116
 but also for novel microorganisms 
51, 105, 107, 114, 117, 118
 from under- or 
un-explored geographical areas
119-122
. Heterologous expression of nonribosomal and cryptic- or 
silent-gene clusters are also currently being used as strategies to explore the production of the 
bioactive secondary metabolites
113, 123-130
. Strains of microorganisms that are currently not cultivable 
pose a challenge as they cannot be used to produce the target compounds at the yields that are 
required for further bioassays and elucidation work. However, successful expressions of biosynthetic 
enzymes and the desired secondary metabolites have been achieved by heterologous expression in 
cultivable host strains, such as Escherichia coli
128, 131-141
, Saccharomyces cerevisae
142-147
 and 
Streptomyces coelicolor
126, 130, 148
.  
Metagenomics has led to the exploration of heterologous expression of biosynthetic gene 
clusters in microorganisms. Indeed, metagenomic approaches have now become essential tools for 
elucidating, defining, and controlling biosynthetic pathways
131
. A key goal of these approaches is to 
develop an efficient  ‘plug and play ? heterologous gene expression platform that  ?  ƚŚƌŽƵŐŚ ‘ŐĞŶŽŵĞ
ŵŝŶŝŶŐ ? ? will facilitate the production of particular target secondary metabolites149, 150 or a plethora 
of new natural products
111, 151-154
.  
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Bacterial or fungal polyketides
125, 129, 153, 155-157
 are chemically diverse and some have 
displayed antibiotic activity by inducing ribosomal frameshift errors
158
   ?  a strategy thought to avoid 
antibiotic resistance mechanisms
159
. However, owing to the intrinsic molecular complexity of 
polyketides, chemical synthesis is not commercially viable. Gene clusters are involved in every step 
of the production of biologically active polyketides
160
, and manipulating the biosynthetic gene 
clusters can allow more economical and efficient production of chirally pure polyketide 
compounds
161
. Two examples, epitholone
162
 and lomaiviticin
163
, are presented in Figure 3.  
Epothilones from the myxobacterium Sorangium cellulosum are potential anticancer drugs 
that act as microtubule disrupters, similar to taxanes
164
. Several epothilone analogues are currently 
undergoing clinical trials: patupilone (also known as EPO-906 or epothilone B) has been through 
Phase III trials in the United States and Phase III trials are ongoing in the United Kingdom, Spain, and 
Greece for ovarian cancer therapy. Ixabepilone (Ixempra; Bristol-Myers Squibb), an analogue of 
epothilone B, has been recently approved in the treatment of breast cancer
165
. The biosynthetic 
gene clusters of epothilones have been widely studied
166, 167
. Recently, a 56 kb epothilone 
biosynthetic gene cluster was reassembled using unique restriction sites (which allowed for future 
module interchangeability) in the guanine- and cytosine-rich host Myxococcus xanthus
168
.  
Genome mining has been used to characterize orphan gene clusters in Salinospora tropica 
CNB-440
150, 169
.  Moore and co-workers utilised genome mining along with a DNA interference 
bioassay-guided approach to investigate two clusters, ST_pks1 and spo, predicted to encode the 
production of DNA-targeting enediynes. However, genetic inactivation of the ST_pks1 and spo 
clusters yielded a mutant incapable of producing enediyne sporolides that still exhibited a similar 
DNA-interfering activity, indicating that enediynes were not responsible for this activity, as earlier 
predicted
170
.  Instead, lomaiviticins  ?  glycosylated polyketides produced by a second cluster, 
ST_pks2  ?  were found to be solely responsible for the DNA-interfering activity of the parent 
strain
150, 169
  
ŐŽŽĚĞǆĂŵƉůĞŽĨŐĞŶŽŵĞŵŝŶŝŶŐ ?ƐŐƌĞĂƚƉŽƚĞŶƚŝĂůŝŶĚƌƵŐĚŝƐĐŽǀĞƌǇŝƐƚŚĞďŝŽƐǇŶƚŚĞƐŝƐŽĨ
pneumocandin B0 (Fig. 3), a lipohexapeptide from the fungus Glarea lozoyensis. Pneumocandin B0 
was derivatized to provide its antifungal semisynthetic congener caspofungin, which is currently 
approved as a treatment against the human pathogenic fungus Candida albicans. Decoding the G. 
lozoyensis genome revealed a rich repertoire of new natural-product-encoding genes 
155
, allowing 
the engineering of novel pneumocandin derivatives with more desirable pharmacological 
properties
155
. 
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The production of anti-infective compounds with novel modes of action has also been 
explored through metagenomics. Guadinomines (Fig. 3) are produced by Streptomyces sp. 
K01-0509
171
 and inhibit the type III secretion system (TTSS) of Gram-negative bacteria. Virulence of 
many pathogenic Gram-negative bacteria  ?  including Escherichia coli, Salmonella spp., Yersinia spp., 
Chlamydia spp., Vibrio spp., and Pseudomonas spp.  ?  requires the TTSS, which acts as a sensory 
probe to detect the presence of eukaryotic organisms and secrete proteins prior to infection
172
. The 
metagenomics-based identification and analysis of guadinomine and its biosynthetic pathway has 
illustrated a means through which guadinomines may be produced with a greater yield
172
.  
Investigation of metabolites ƵƐŝŶŐ ?ŽŵŝĐƐĂƉƉƌŽĂĐŚĞƐ. The supply problem of many novel and 
potent natural products that occur as minor metabolites may be solved by overexpression
131, 161
 of 
their biosynthetic gene clusters in cultivable organisms
173
, although it remains to be seen if this can 
be routinely achieved on a production scale. 
Overexpression and antisense suppression strategies have been applied to transgenic plants. 
For example, the overexpression of several key gene-encoding enzymes  ?  for flavonoids or 
isoflavonoids
174
, or in terpenoid pathways
175
  ? increases production, thereby circumventing seasonal 
and geographical limitations. The soybean isoflavone synthase (IFS) was introduced to plants such as 
tobacco, petunia, and lettuce, that do not naturally produce isoflavonoids, enabling these plants to 
biosynthesise the isoflavanone genistein
176
. Genistein yield was improved in tobacco by suppressing 
flavanone 3-hydroxylase (F3H) expression through an antisense approach. F3H is a dihydro-flavonol 
reductase which catalyzes the synthesis of dihydroflavonols and anthocyanin. Impairing F3H with the 
introduction of IFS, elevated genestein production.  Overexpression of IFS and phenylalanine 
ammonia-lyase (PAL) in tobacco petals and lettuce leaves both also led to an increase in genistein 
production. Moreover, the presence of both IFS and PAL gave a more substantial increase in 
genistein yield than in plants in which only IFS was overexpressed
176
.  
The tobacco plant Nicotiana benthamiana has also been explored as a production platform 
for precursors of artemisinin, which is usually extracted from Artemesia annua, for the treatment of 
malaria
177
. Genes for three biosynthetic enzymes necessary to produce artemisinic acid (Fig. 4) were 
expressed by agro-infiltration of N. benthamiana.  This heterologous pathway in the tobacco plant 
yielded approximately double the artemisinic acid-12-beta-diglucoside than did Artemesia annua
178
. 
The Keasling group in University of California, Berkeley, USA, used the combined expression of A. 
annua artemisinic aldehyde dehydrogenase (ALDH1) and artemisinic alcohol dehydrogenase (ADH1) 
in engineered strains of S. cerevisiae to give a high yield of artemisinic acid
179, 180
. Artemisinic acid is 
converted to artemisinin in a two-step reaction via reduction of the exocyclic methylene group and 
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simultaneous photooxidation (Fig. 4)
181
. The World Health Organization has recently approved the 
preparation of semi-synthetic artemisinin that is functionally equivalent to the plant-derived drug
180
. 
Sanofi has taken over the industrial-scale production of semi-synthetic artemisinin to be used to 
supplement the world supply
180
. 
Microorganisms such as E. coli
134, 140, 141
and S. cerevisae
144, 146
 have been used as platform 
hosts for heterologous pathways of plant-extracted flavonoids for nutraceuticals and drug 
development
174
. The bioactive flavonoid 7-O-methyl dihydrokaempferol (7-O-MeDHK) has been 
isolated from different plants, but an  ‘E. coli cell factory ? was established to increase 7-O-MeDHK 
production from its precursor, p-coumaric acid
134
. E. coli were primarily fed with p-coumaric acid to 
allow synthesis of naringenin (NRN); a related flavanone
182
) which was further derivatized 
enzymatically to 7-O-MeDHK. The flavanone biosynthetic pathway was reconstructed in E. coli that 
expressed three structural genes from three different plant species: 4-coumarate-coenzyme A (CoA) 
ligase from Petroselinum crispum; chalcone synthase from Petunia hybrid; and chalcone isomerase 
from Medicago sativa, resulting in a yield of 119 mg NRN per litre of 3 mM p-coumaric acid
183
. 
However, one limitation of the procedure is that E. coli produces very low levels of intracellular 
malonyl-CoA, which is a crucial precursor in the flavanone biosynthetic pathway. The low levels of 
precursor is a potential barrier in employing E. coli for commercial-scale production of flavonoids 
and also other important polyketides. In a more recent study, the intracellular malonyl-CoA pathway 
was engineered in E.coli by inducing the overexpression of acetyl-CoA carboxylase and acetyl-CoA 
synthetase genes from N. farcinica, and this gave a 2.3-fold increase of malonyl-CoA levels in 6 hours 
and consequently yielded a 2.2-fold increase in the production of NRN over 24 hours upon feeding 
with 250 PM p-coumaric acid 134.  
In the case of natural products that are sourced from marine invertebrates  ?  such as 
sponges, soft corals, tunicates and bryozoans  ?  metagenomics technology can promote 
sustainability and ecological preservation of coral reefs and oceans
110, 114
. Marine organisms have 
provided many promising bioactive compounds with exciting therapeutic potential, but their 
development has been severely curtailed, owing to the difficulties in obtaining adequate amounts. 
For example, the anticancer agent ecteinascidin-743 (also known as trabectedin; trade name 
Yondelis; Zeltia/Johnson & Johnson) (Fig. 3) was first isolated from the sea squirt Ecteinascidia 
turbinata in 1984. However, yields from the sea squirt were extremely low: one tonne of animals 
was needed to isolate one gram of trabectedin. It was only after 15 years that the supply problem 
was resolved by a semisynthetic process that is initiated with safracin B, which is obtained by 
fermentation of the bacterium Pseudomonas fluorescens.  
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Natural products that are derived from marine microorganisms often show pronounced 
similarities, or are even identical, to compounds from sponges, tunicates or other marine 
invertebrates. Some of these microorganisms (most of which are currently not cultivable) are now 
considered to be the true producers of such bioactive constituents
184
. The oceans are known to 
contain an average of 10
5 ?106 bacteria alone per millilitre sea water, totalling an estimated bacterial 
weight of 10
12
 tonnes. Genomic mining has played an important part in exploiting both the bacteria, 
and the sponges in which they are found, for their biosynthetic genes
106, 110, 112, 114, 185, 186
.  
One example of natural products that are produced by marine invertebrate-associated 
bacteria is the group of antimalarial manzamine alkaloids (Fig. 3) that were originally isolated from 
the Acanthostrongylophora sponges, and later from the sponge-associated actinomycete 
Micromonospora
187
. Another example is the group of patellamide peptides (Fig. 3), which are active 
against multidrug-resistant cancer-cell lines; these peptides  were first isolated from the tunicate 
Lissoclinum patella, but were then found to be produced by its cyanobacterial symbiont Prochloron 
didemi
188
.  
The biosynthetic pathway for the potent antitumour agent psymberin (Fig. 3) from the 
sponge Psammocinia aff bulbosa was obtained through structure-base gene targeting of the 
biosynthetic polyketide synthase genes from its uncultivated sponge-associated bacteria184. Strikingly, 
the analysis of the sponge metagenome suggested that a non-cultivated bacterial symbiont may in 
fact be the true producer of sponge products, including the marine sponge-derived 
polytheonamides.
189, 190
 Polytheonamides are ribosomally synthesized peptides and, through 
metagenomic mining, the biosynthetic scope of ribosomal systems has expanded, opening new 
doors for peptide and protein bioengineering
190
.  
Opportunities for natural products  
There are many examples of natural products being used in drug discovery efforts that are directed 
at a wide range of indications. For example, herbal medicines and isolated compounds have been 
ƚĞƐƚĞĚŝŶŵŽĚĞůƐŽĨůǌŚĞŝŵĞƌ ?ƐĚŝƐĞĂƐĞ191-193 and of diabetic neuropathy194. Here, we will focus on 
two major areas: antimicrobials, and modulators of protein ?protein interactions. 
Antimicrobials. Natural products have provided the starting points for most of the major classes of 
antibiotics, including the E-lactams, aminoglycosides, macrolides, tetracyclines, rifamycins, 
glycopeptides, streptogramins and lipopeptides. Since 2000, 22 new antibiotics have been launched 
for treating infections in humans, but only five of these represented new classes of compound
8
. 
Three of these new classes have their origins in natural products: the lipopeptide daptomycin, the 
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pleuromutilin retapamulin, and the tiacumicin fidaxomicin. Butler et al.
8
 identified 56 antibiotics that 
were undergoing clinical trials in 2013. Of these, nineteen represented new structural templates and 
eleven were natural-product-related (Table 3). In the last 30 years, natural-product research has also 
provided the only new class of antifungal drugs, the echinocandins
195
. 
There are still pressing needs for new and better anti-infectives. The current rate of the 
introduction of new antimicrobials may not be sufficient to cope with the emergence of bacteria and 
fungi that are resistant to available agents
196-199
. The situation is particularly acute in the case of 
drug-resistant Gram-negative bacterial infections, because very few new compounds are in 
development for such uses
200
. The question is whether or not natural products can be useful in 
finding such agents.  
Following the completion of the first DNA sequencing of a bacterial genome in 1995 and the 
development of genomic technologies, antibiotic discovery switched from traditional functional 
screening to target-based HTS. Genes that are specific to bacteria were deleted to determine which 
genes were essential for bacterial viability
201
 and to identify antibacterial targets. However, such 
efforts have not yielded the success that was anticipated
201-203
 and no new drugs emerged
204-206
. A 
ĚĞƚĂŝůĞĚĂŶĂůǇƐŝƐŽĨ'ůĂǆŽ^ŵŝƚŚ<ůŝŶĞ ?ƐĂŶƚŝďĂĐƚĞƌŝĂůĐĂmpaigns revealed that 67 HTS campaigns 
against targets that were selected from a panel of 160 genes that had been predicted to be essential 
for microbial viability failed to generate candidates for clinical development
203
. Other companies 
appear to have had similar experiences
204
. 
The lack of success of the target-based approach is probably owing to a combination of 
three factors. First, identifying functionally essential targets in microbes turned out to be more 
complicated than had been expected because of inherent biological complexities. Second, the 
challenges of moving from hits in a molecular screen to a compound that could reach its intracellular 
target at an effective concentration were underestimated. Third, the chemical libraries that were 
used for screening were not sufficiently biologically relevant
202, 204-206
. Moreover, it has also been 
argued that a focus on genomically predicted targets that are single enzymes means that any 
compounds that are found to be active are liable to trigger drug-resistance mechanisms
204
. 
Perhaps the promise that was offered by genomic approaches took attention from the fact 
that successful development of antibacterial drugs is always particularly challenging
202, 204, 206
. 
Antibacterials will generally induce the development of resistance mechanisms in the target species, 
thus rapidly limiting ƚŚĞĚƌƵŐ ?Ɛusefulness. The wide range of drug-resistance mechanisms means 
that it is increasingly difficult to create new drugs by modifying existing chemical classes. The 
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penetration of compounds through bacterial cell walls and particularly through the additional outer 
membrane of Gram-negative bacteria is not currently predictable. Compounds also have to avoid 
the various efflux mechanisms in bacteria. Plasma concentrations of antibiotics generally have to be 
much higher than those for other drugs in order for the antibiotic to penetrate to its target within 
the cell, meaning that the antibiotic must have an exceptionally wide margin of safety to avoid toxic 
effects in the patient.  
With these obstacles in mind, many research groups are exploring how to make better use 
of screening that is based on whole organisms, and there is a returning interest in using natural 
products in screening. However, there are difficulties of screening traditional sources (namely, 
microbial broths) because of the frequent re-discovery of known compounds. Improvements in rapid 
dereplication are necessary
56, 58
. Alternatively, other natural products  ? from different sources  ?  
could be tested. These could include microbial products of activated cryptic pathways (see 
elsewhere in this review) or secondary metabolites from plants
207-212
, endophytic fungi
213
, or marine 
sources
214
.  
To increase the resolution of screening assays, target microbes can be made more sensitive 
to compounds that have particular mechanisms of action by manipulating the levels of a specific 
target protein or the activity of a certain pathway, for example through the use of siRNA or genetic 
engineering. This approach is exemplified by the discovery of inhibitors of the FabF and FabB 
enzymes (for example, platensimycin
215
, which has been reviewed by Martens and Demain
216
) and 
cell division protein FtsZ inhibitors
217
. Collections of bacterial and yeast strains with knockdown or 
overexpression of particular genes are available, along with information on identified genes that are 
essential for, for example, E. coli
218
, S. aureus
219
 or Saccharomyces cerevisiae
220, 221
.  
Whole-cell screening can be used in determining mechanisms of antimicrobial action by 
identifying resistant strains, which can be subsequently sequenced to locate functionally important 
genes
205
. Using drug-resistant mutants, a group of natural products called acylydepsipeptides were 
discovered to disrupt a bacterial protease
222
; potentially, these acylydepsipeptides represent a new 
class of antibiotic. Collections of mutant yeast strains have also been used to uncover mechanisms of 
action
220, 221
, and such approaches have been successful with natural product extracts
223
, as 
exemplified by the screening that led to the isolation and identification of parnafungin from a 
culture of Fusarium larvarum
224
. Parnafungin inhibits poly(A) polymerase in Candida albicans and 
was found to have broad activity against a range of pathogenic fungi, and to be beneficial in an 
animal model of candidiasis. 
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Another functional approach to uncovering novel activities in whole-cell screens involved 
creating antibiotic mode-of-action profiles (BioMAPs) of 72 known antibiotics against 15 relevant 
strains of Gram-positive and -negative bacteria
36
. Subsequently, BioMAP testing of 3120 
prefractionated extracts from a marine natural-product collection revealed 83 fractions that 
produced novel patterns of activity. Novel compounds were isolated, whereas known compounds 
could be readily identified and disregarded. The BioMAP tool has been made available for use by 
other researchers
36
. Information of the activities of 7500 compounds on yeast cells is also available 
as a public resource to help find compounds that may be active in phenotypic assays in other model 
organisms
225
.  
Simpler approaches to functional screening can still be successful. One example is an assay 
that identifies inhibitors of bacterial sugar metabolism
34
, which was used to screen a collection of 
over 39,000 partially purified microbial extracts from Costa Rica against a sucrose-dependent strain 
of Vibrio cholera. A mutant strain of V. cholera that does not transport sucrose was also used in 
screening the same compounds, so that bacteriostatic and bactericidal effects could be 
distinguished. One of 49 initial hits was followed up in detail: it was a novel compound, later 
identified as 6-propyl gentisyl alcohol. This molecule had activity against other Gram-positive 
species, but it remains to be seen whether it is non-toxic and whether its rather low potency can be 
improved by structural modifications.  
Other assays have gone beyond tests on growth of the target microorganisms alone to 
screening based on infections in model organisms, including in the nematode Caenorhabditis 
elegans
226
 and the zebrafish Danio rerio
227, 228
. For example, an automated screening system that 
models Enterococcus faecalis infection in C. elegans
229
 was established to screen natural products in 
the form of either extracts or pure compounds. The hit rate that was reported for a collection of 
purified natural products was several times that from synthetic chemical libraries. An advantage of 
such systems is that the assay can detect activities that treat infections by mechanisms other than 
classical antibiotic actions. 
With the growing awareness of the power of functional assays for antimicrobial activity, and 
the appreciation of the advantages of natural-product screening libraries, there is likely to be an 
increase in the use of natural products to find leads with novel antibiotic of antifungal properties. A 
similar trend has been evident in the interest in seeking compounds that affect interactions between 
proteins. 
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Protein ?protein interactions. Protein ?protein interactions are generally regarded as difficult targets 
for small molecules
230-232
, although such interactions play many critical roles in physiology and may 
therefore represent important therapeutic targets. Screening natural products may be more 
successful than screening conventional collections of compounds, because the more complex shape 
and larger size of natural products may make them more likely to perturb interactions between large 
areas of the involved proteins. As discussed below, several natural products have potent activity at 
inhibiting or promoting protein ?protein interactions. Besides the use of natural products, other 
approaches to the discovery of protein ?protein interaction-influencing drugs include 
peptidomimetic design, fragment-based drug discovery and virtual screening, and they have also had 
some successes (see reviews 
231,233, 234
). 
In theory, inhibitors of protein ?protein interactions may have more selectivity than, for 
example, inhibitors of the active sites of enzymes, because there may be more structural diversity in 
protein ?protein interactions than in active sites. Inhibitors may block interactions by binding to 
critical regions of one (or more) of the proteins, or via an allosteric mechanism
232
. Some early 
examples of such inhibitors have been described
235
. Stabilizers (rather than disruptors) of protein ?
protein interactions have also been reviewed
236
. Some of such stabilizing compounds were found 
after phenotypic effects that are caused by natural products had been noted and even marketed. 
Examples of such compounds include paclitaxel (which stabilizes microtubules), rapamycin (also 
known as sirolimus) and tacrolimus (also known as FK506). Both sirolimus and tacrolimus bind to the 
immunophilin FKBP12. The sirolimus ?FKBP12 complex then binds to mammalian target of rapamycin 
(mTOR) ?ƚŚĞƌĞďǇŝŶŚŝďŝƚŝŶŐŵdKZ ?ƐĞŶǌǇŵĂƚŝĐĂĐƚŝǀŝƚǇ ?ƚŚĞtacrolimus ?FKBP12 complex binds to and 
inhibits calcineurin. More detailed information about protein ?protein interactions and disruptive 
compounds is collated in the 2P2I (Protein ?Protein Interaction Inhibition) and TIMBAL databases237, 
238
.  
The interaction between the tumour-suppressor protein p53 and its regulatory protein 
MDM2 (murine double minute 2 protein) has served both as a model for protein ?protein 
interactions and as a challenge to find potent and selective inhibitors
239, 240
. p53 regulates the cell 
cycle in response to stress and its function is dysregulated in many cancer cells, making it an 
important therapeutic target. Derivatives of the natural product chalcone were revealed by enzyme-
linked immunosorbent assays (ELISA) and NMR assays to disrupt the p53 ?MDM2 interaction241. 
Screening of a large collection of microbial extracts led to the identification of chlorofusin as an 
inhibitor of the p53 ?MDM2 interaction242. Chlorofusin is a relatively large and complex molecule (it 
has a molecular mass of 1,363 Da), although it has been synthesized
243
. Another compound-
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collection screen uncovered more potent p53 ?MDM2 inhibitors, including nutlin-3244. Nutlin-3 has a 
half-maximal inhibitory concentration (IC50) of 90 nM, and exhibits activities against several cancer 
cell lines in vitro and in various animal tumour models. Now known as RG7112 or RO5045337, it has 
completed Phase I trials in various cancers, but has not yet progressed further
245
. A tryptamine-
derived compound (JNJ-26854165, also known as serdemetan) has also been in Phase I trials in 
patients with solid, refractory tumours
246
. This compound had previously been shown to be active in 
several in vivo cancer models and has more recently been found to inhibit cholesterol transport in 
cancer-cell lines
247
, an action that might contribute to its anticancer activity in vivo. 
Most of the assays that are used to detect disruption of protein ?protein interactions involve 
sophisticated detection methods such as fluorescence polarization
248
, surface plasmon resonance 
and NMR
249
. A relatively simple and direct assay was described
250
 that uses phage display with p53 to 
monitor binding to MDM2. This enabled the rapid screening of a small collection of natural products 
isolated from mosses and fungi. From this screen, the previously known bioactive compound 
dehydroaltenusin was identified as inhibitor of the p53 ?MDM2 interaction, although it was about 
100-fold less potent than nutlin-3
250
. 
The BCL-2 (B-cell lymphoma-2) family of proteins regulate apoptosis. Anti-apoptotic 
members (such as BCL-XL), which are commonly overexpressed in cancer cells, dimerize with pro-
apoptotic members (such as BAC or BAX). Two natural products, gossypol and purpurogallin, were 
found to inhibit binding of BCL-XL with the D-helical domain of pro-apoptotic proteins251. Gossypol 
and its derivatives inhibit the growth of cancer-cell lines and show anticancer activity in animal 
models
252
. Although earlier trials with racemic gossypol were not successful, a single enantiomer of 
gossypol (called AT-101) is now in clinical trials in patients with different forms of cancer
253
. Newer 
analogues of gossypol are also being tested in cancer
254
, but it remains to be seen whether or not 
they will be successful. Thus, the experimental studies with gossypol paved the way to synthetic 
inhibitors of BCL-2 that are now in clinical trials
254
. 
There are also examples of natural products as inhibitors of protein ?protein interactions 
that have not yet led to clinical development candidates. Thymoquinone, and its synthetic derivative 
poloxin inhibited the interaction between polo-like kinase 1 and its intracellular anchoring site
248
. 
These inhibitors induced mitotic arrest and apoptosis in HeLa cells
248
. Rosmarinic acid and salvianolic 
acids blocked some interactions of the SH2 domain of Src-family tyrosine kinases with labelled 
peptides that were designed to mimic the binding domain of the erythropoietin receptor
255
. An HTS 
assay that tested for interactions of various proteasome assembling factors was used to screen a 
collection of over 123,000 extracts and over 4,000 isolated compounds
35
. Several potent blockers of 
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the homodimerization of proteasome-assembling chaperone 3 (PAC3) were found. One fungus-
derived compound had an IC50 of 20 nM, but its structure was not determined. Another sponge-
derived compound, JBIR-22, was later found to be an analogue of equisetin, an antibiotic compound 
produced by Fusarium spp.
256
. JBIR-22 was shown to be cytotoxic to HeLa cells
256
, but it was not 
otherwise characterized for biological activity. 
Natural products have also been used to disrupt interactions between proteins and RNA. For 
example, spliceostatin A (which is a synthetic derivative of a natural product from a broth of a 
Pseudomonas species) blocks splicing and nuclear retention of pre-mRNA, probably by binding to the 
SF3b complex of the U2 small ribonucleoprotein and blocking its association with the U2 small-
nuclear-RNA auxiliary factor
257
. The spliceostatin A analogue FR901464 kills tumour cells in vitro and 
prolongs survival in mouse cancer models
258
, and simpler spliceostatin A analogues (such as 
sudemycins) are also being studied as possible anticancer leads
259
. Didehydro-cortistatin A (a 
synthetic variant of the steroidal alkaloid corticostatin A from the marine sponge Corticum simplex) 
binds specifically to the transactivation-responsive (TAR) domain of the HIV TAT (trans-activator of 
transcription) protein, inhibiting its binding to HIV mRNA
260
. This prevents transcription, and 
decreases HIV-1 and HIV-2 replication and reduces the release of viral particles from CD4
+
 T cells
260
. 
Overall, protein ?protein interactions are being recognized as potentially druggable targets, 
and natural products are likely to provide more leads for future developments. 
Conclusions and outlook 
Although natural products have been extensively used in historical drug discovery efforts
3, 4
, there 
are still many resources that could be explored in modern natural-product research
1, 5-7, 261
. The 
Dictionary of Natural Products has recorded approximately 200,000 plant secondary metabolites to 
date, including about 170,000 unique structures after removal of duplicates. Approximately 15% of 
the drug interventions in ClinicalTrials.gov are plant-related, with about 60% of theƐĞĚƌƵŐƐ ?
sources
262
 clustered from within only 10 taxonomic families
263
. Despite these successes, it is likely 
that the vast majority of plant species have not been systematically investigated in drug discovery 
campaigns. Even the traditional plant-based medicines that are used by different cultures still need 
to be more thoroughly explored.  
In addition, microorganisms demonstrate a magnitude of biodiversity that surpasses those 
of eukaryotes, and can have exceptional metabolic adaptability. For these reasons, microorganisms 
thrive in even the most extreme environmental conditions, and such microbial communities exhibit 
unique prokaryotic diversity. They can be considered as  ‘bacterial hotspots ?. However, less than 1% 
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of this vast biodiversity has been investigated, mainly owing to non-cultivability in the laboratory. 
Using metagenomic and heterologous-expression techniques, we can gain better access to a richly 
diverse microbial community
264
, and potentially advantage from a boundless source of novel 
bioactive compounds. 
Looking forward, recent technological advances could be sufficient to revitalize the 
exploitation of the value of natural products as starting points for drug discovery, particularly with 
the recent growth in interest in phenotypic screening. Understanding the physicochemical 
properties of natural products in order to allow drug development is no different to normal 
medicinal chemistry principles that are applied to synthetic compounds. The fact that drug-like and 
lead-like properties can be predicted and experimentally enriched at the fraction-library level
33
 
allows a front-loading of natural-product drug discovery that is aligned with best-practice medicinal 
chemistry. Natural products inherently fall in regions of biologically relevant chemical spaces  ?  as 
illustrated by recent studies that correlate interactions in biosynthetic production of secondary 
metabolites with similar interactions against validated drug targets. The scaffolds of natural products 
allow the generation of libraries that escape  ‘flat-land ? and retain highly relevant the three-
dimensional aspects that are characteristic of natural products. Such three-dimensional attributes of 
unique natural scaffolds take the generation of chemical libraries into new territory. Whereas the 
concept of natural-product-inspired scaffolds aims to use chirality and non-flat attributes, natural-
product-derived scaffolds have the advantage of using the known protein surface interactions of 
natural products in biosynthetic enzymes. It remains to be seen how effective the two scaffold 
strategies will be in the future. In our view, the natural-product ?protein interaction that exists in 
natural-product-derived scaffold mechanisms is more biologically relevant and may prove in the 
long-term to be superior to random three-dimensional (or non-flat ) structures in terms of their 
ability to modulate interactions with proteins that are important in disease states.  
This field of research has been enhanced by a rich source of novel compounds from non-
traditional sources, such as novel microorganisms. The introduction of recent complex marine 
natural products to the market
265
  ?  including anticancer drugs such as the monomethyl aurostatin 
E, a synthetic analogue of dolastatin 10
266
 from the sea hare Dolabella auricularia , which is a 
component of the antibody-drug conjugate brentuximab vedotin (Adcetris; Seattle Genetics); 
eribulin mesylate (Halaven; Eisai Co.), an analogue of halichondrin B
267
 from the sponge Halichodria 
okadai
268, 269
; trabectidin
270
 (Yondelis; Zeltia/Johnson and Johnson), a drug derived from the tunicate 
Ecteinascidia turbinata; and the neuropathic pain drug ʘ-conotoxin (also known as ziconotide271 
(Prialt; Eisai Co./Jazz Pharmaceuticals) from the marine snail Conus magus  ?  has also highlighted 
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that process chemistry can deliver sufficient quantities of such molecules if their therapeutic activity 
is sufficiently compelling. Encouraging more companies to adopt natural product-based screening, 
however, requires more natural-product researchers to utilize the recent technological advances 
effectively. 
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Box 1 The United Nations Convention on Biological Diversity and the Nagoya Protocol 
The United Nations Convention on Biological Diversity (CBD, http://www.cbd.int/convention/text) 
arose from the Rio Earth Summit in 1992. It sets out the expectations around access to, and the use 
ŽĨ ?ďŝŽĚŝǀĞƌƐŝƚǇ ? ‘ŐĞŶĞƚŝĐƌĞƐŽƵƌĐĞƐ ? ?ĂĐƌŽƐƐŶĂƚŝŽŶĂůďŽƵŶĚĂƌŝĞƐ ?ƌŽĂĚůǇ ?ƚŚĞƐƚĂƚĞƐƚŚĂƚ P 
x countries have sovereign rights over the genetic resources in their territories 
x access to genetic resources by foreign groups requires prior informed consent from the 
appropriate authority in the source country 
x access on mutually agreed terms should be facilitated by the source country 
x benefits from the use of genetic resources should be shared in a fair and equitable way with 
the source country 
x the source country should be involved in relevant research on the genetic resources, where 
possible, and benefit from technology transfer 
The CBD was signed by most countries in the world (194 to date), and has been extensively ratified 
(with the notable exception of USA). However, because the CBD requires individual countries to 
adopt suitable laws and regulations to implement its principles, the impact of the CBD has been 
varied. 
The CBD did not have specific recommendations that addressed use of traditional knowledge from 
one group of people by other groups or companies. This was the subject of the Nagoya Protocol, 
which was adopted in October 2010 by the Conference of the Parties to the CBD 
(http://www.cbd.int/abs/text/default.shtml). This Protocol gives detailed suggestions that cover 
access and benefit-sharing with respect to natural products and traditional knowledge. The Protocol 
has been signed by 92 countries (as of November 2014), but only ratified by 30 countries, with 
EŽƌǁĂǇďĞŝŶŐƚŚĞĨŝƌƐƚ ‘ĚĞǀĞůŽƉĞĚ ?ĐŽƵŶƚƌǇƚŽĚŽƐŽ ?&ŝĨƚǇĐŽƵŶƚƌŝĞƐŚĂǀĞƚŽĂĚŽƉƚƚŚĞWƌŽƚŽĐŽů
before it has legal force. However, it can be regarded as a practical guide to those working on 
biodiversity and making use of traditional knowledge. 
For further discussion on the impact of the CBD and the workings of the Nagoya Protocol, see 
references 
2,272, 273, 274
. 
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Box 2: Advances in NMR techniques   
Driven by the enhanced sensitivity of NMR microcryoprobes, the ability to elucidate chemical 
structures of natural products using nuclear magnetic resonance (NMR) spectroscopy has now 
reached the stage where structures can be solved using very small quantities (in the microgram 
range). At such sensitivity, synthesis of the isolated compounds will be required to allow subsequent 
full biological evaluation. Examples of compounds and the mass from which their structure was 
solved are as follows: 
x  9-O-Desmethylkabiramide B (620 ʅg) 275, 276  
x Sanguinamides A and B (390 ʅg and 190 ʅg, respectively) 275, 276.  
x Phorbaside F (7.5 ʅg), 275, 276 
x Hemi-phorboxazole A (16.5 ʅg)275, 276 
x Muironolide A (90 ʅg) 275-277 .  
x Combretasides A ?G (new acetylated dammarane-type bisdesmosides) (29 ?187 ʅg)278  
x Beilschmiedic acids O(41.9 ?220 ʅg)279. 
x One previously known (120 ʅg), and three new (60 ʅg, 180 ʅg and 5 ʅg) stilbenoids279, 280,281. 
Structure elucidation of novel natural products demands two-dimensional NMR experiments. 
Hyphenated (combined) techniques such as high-performance liquid chromatography (HPLC) ?NMR 
use stopped-flow, and thus allow for smaller quantities to be used
282
. 
 
One structural difficulty with natural products is that they are frequently isolated as a single 
diastereoisomer
283
, meaning only one set of NMR measurements is possible. Although ab initio 
(quantum chemstry)  calculation of NMR chemical shifts is a powerful tool for assigning 
stereochemistry to molecules
284, 285
, having just one data set for a single diastereoisomer provides an 
additional challenge in determining the stereochemistry
283
. A probability method of determining 
stereochemistry that is based on conformational analysis of diastereomers has been successfully 
demonstrated for 36 structures
283
.  
Complex mixtures of metabolites can be elucidated using another two-dimensional technique: J-
resolved NMR. This method can be used to resolve overlapping signals by separating the effect of J-
coupling
72
 from the effect of chemical shifts. The magnitude of the J-coupling signal provides 
information on bond distance and bond angles: information that ĐĂŶďĞĐŽƌƌĞůĂƚĞĚƚŽĂĐŽŵƉŽƵŶĚ ?Ɛ
stereochemical features.  
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Fig 1. Biologically relevant chemical space is better covered by natural products than by synthetic 
compounds. (A) There are 22,724,825 commercially-available compounds in the Zinc database, 
286
 as 
represented by the blue circle. By comparison, there are around 160,000 unique natural products in 
the Dictionary of Natural Products, represented in approximate scale by the small orange circle. (B) 
Compounds that are biologically relevant ďǇĚĞĨŝŶŝƚŝŽŶ ‘hit ? a biological target. The Zinc database 
(represented by the red square) is designed to allow virtual screening of listed compounds, which 
are in ready-to-dock 3D formats. The typical size of physical screening libraries ranges from 100,000s 
to millions of compounds. Screening libraries may be chosen to conform to >ŝƉŝŶƐŬŝ ?Ɛrule-of-five 
(represented by the pink square), or to be lead-like (represented by the orange square) with reduced 
molecular mass and lipophilicity. The Zinc database ?Ɛ drug-like subset consists of 15,798,630 
compounds, whereas the same database ?Ɛ lead-like subset comprises 6,687,370 compounds. 
Considerable effort, knowledge and expertise is required to select a specific screening subset that is 
enriched with biologically relevant compounds (represented by the green square). By contrast, all 
natural products occupy biologically relevant chemical space (as described by Protein Fold 
Topology
40, 41
), and around 80% of natural products conform to the rule-of-five and are drug-like 
42
.  
 
Figure 2. Metabolomics data workflow in natural product research. Samples were submitted to LC-
HRFTMS, LC-PDA, and LC-1D/2D NMR analysis. The mass spectrometry data were further processed 
utilizing differential expression analysis softwares like MZmine, MZmatch, and XCMS. These 
softwares were coupled to databases such as DNP, Antibase, or MarinLit to dereplicate known 
natural products against the novel secondary metabolites. Pre-collected LC-PDA and LC-1D/2D NMR 
data confirmed the dereplication results. The processed data were subjected to multivariate analysis 
employing both PCA and/or OPLS-DA. The results were then plotted in S-plots and heat maps.  
Through pattern recognition, inactive vs active and known vs novel natural products were sorted to 
define the natural products that will be targeted for further isolation and scale-up work. (LC-
HRFTMS: hyphenated Liquid Chromatography-High Resolution Fourier Transform Mass 
Spectrometry; LC-PDA: hyphenated Liquid Chromatography-Photodiode Array; LC-1D/2D NMR: 
hyphenated Liquid Chromatography-one dimensional/two dimensional Nuclear Magnetic Resonance 
spectroscopy; DNP: Dictionary of Natural Products; PCA: Principal Component Analysis; OPLSDA: 
orthogonal partial least squares discriminant analysis) 
 
Fig. 3. Structures of biologically active natural products or natural-product-derived compounds. 
a | Anticancer lomaiviticins are complex glycosylated diazofluorene polyketides that were originally 
discovered from Salinispora pacifica strain DPJ-l0019 (formerly known as Micromonospora 
 40 
 
lomaivitiensis)
150
. The diazobenzo[b]fluorene ring moiety of lomaiviticins interacts directly with 
DNA
287
. b ?c | Ixabepilone (c) Ixempra; Bristol-Myers Squibb), an analogue of epothilone B (b), was 
approved by the US Food and Drug Administration in 2007 for the treatment of aggressive 
metastatic or locally advanced stages of breast cancer. To increase production yield, and to 
efficiently derivatize a variety of analogues with improved bioactivity, the epothilone biosynthetic 
gene cluster from S. cellulosum was redesigned and reassembled for expression in Myxococcus 
xanthus
168
. d ?e | The pneumocandin biosynthetic gene cluster from Glarea lozoyensis (wild-type 
strain ATCC 20868) was shown to contain a nonribosomal peptide synthase GLNRPS4; a polyketide 
synthase GLPKS4 in tandem duplications; two cytochrome P450 monooxygenases; seven other 
modifying enzymes; and five continguous genes for the biosynthesis of L-homotyrosine (a 
component of pneumocandin  ? ?Ɛ peptide core). Disruption of GLNRPS4 or GLPKS4 resulted in loss 
of antifungal activity
155
. f | Guadinomines inhibit the type III secretion system (TTSS), which is 
responsible for the virulence of many pathogenic Gram-negative bacteria
171
. The guadinomine gene 
cluster was identified by targeted disruption of the gene cluster, as well as by heterologous 
expression and analysis of key enzymes in its biosynthetic pathway
288
. g ?j | Examples of natural 
products that are produced by marine invertebrate-associated bacteria. g | Manzamines are 
antimalarial alkaloids that were originally isolated from the Acanthostrongylophora sponges, and 
later from the sponge-associated actinomycete Micromonospora
187
. h | The patellamide peptides, 
including patellamide A shown here, were isolated from the tunicate Lissoclinum patella but then 
found to be produced by its cyanobacterial symbiont Prochloron didemi
188
. Patellamide peptides are 
active against multidrug-resistant cancer-cell lines. i | The anticancer agent ecteinascidin-743 (also 
known as trabectedin; Yondelis; Zeltia/Johnson & Johnson) was first isolated from the sea squirt 
Ecteinascidia turbinata in 1984. Its supply difficulties were later resolved by a semisynthetic process 
that commenced with safracin B that was obtained via fermentation of the bacterium Pseudomonas 
fluorescens. j | The potent antitumour agent psymberin from the sponge Psammocinia aff bulbosa 
has been demonstrated to be produced by the biosynthetic genes of its uncultivated sponge-
associated bacteria by structure-based gene targeting
184
.  
 
Fig. 4. Structures of artemisinic acid and artemisinin. The antimalarial drug artemisinin (right) is 
usually extracted from Artemisa annua, but yields of arteminisinic acid (left) from heterologous 
expression systems in the tobacco plant are higher. Therefore, it is more economical to convert 
arteminisinic acid to artemisin via a two-step reaction.  
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Table 1. Pre-fractionation strategies.  
Institute No. of fractions* No. of Samples Method of generating 
fractions  
Ref.
 
MerLion 4 HPLC fractions 
per sample 
<120,000 C18 HPLC 
28
 
Sequioa Sciences 40 HPLC fractions 
on 5 sub-fractions 
(200 fractions per 
sample)  
36,000 fractions, 
with each well 
containing 
approximately 1 ?
5 compounds  
Organic extract: silica FC 
(to give 4 fractions), 
followed by HPLC (to 
give 40 fractions); 
aqueous extract: 
pretreated C18 FC, 
polyamide 
chromatography, 
molecular weight filter, 
then HPLC (to give 40 
fractions) 
27 
Wyeth 10 HPLC fractions 
per sample 
<6,500 C18 HPLC  
29
 
Ireland Lab 
(University of 
Utah, USA) 
20 HPLC fractions 
from 4 sub-
fractions (80 
fractions per 
sample) 
15,360 Synthetic adsorbent 
separation, followed by 
C18 HPLC 
30
 
Guy and Yan 
Group (St Jude 
ŚŝůĚƌĞŶ ?Ɛ
Research 
Hospital, 
Tennessee, USA) 
24 fractions <62,000 Polyamide FC, C18 HPLC  
31
 
RIKEN, Japan Up to 325 fractions 
per sample  
~6,500 semi-
purified natural-
product fractions 
LC ?MS 32 
Quinn Lab (Eskitis 
Institute, Griffith 
11 HPLC fractions 
per sample 
202,983  Oasis HLB, followed by 
C18 HPLC 
33 
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University, 
Brisbane, 
Australia)  
Watnick Lab 
(Children's 
Hospital, Boston, 
USA) 
 39,000 Pre-fractionated 
34
 
Biomedicinal 
Information 
Research Center 
(Japan) 
 123,599 Fractionated to give 
crude metabolites 
35 
Linington Lab, 
Santa Cruz 
6 fractions per 
sample 
3,120 Solid phase extraction 
C18 reverse-phase 
chromatography 
36
 
*Reports of approaches range widely in the number of fractions prepared from each sample, from 
four fractions to 200 fractions. FC, flash chromatography; HPLC, high-performance liquid 
chromatography; HLB, hydrophilic ?lipophilic balance separation; LC ?MS, liquid-chromatography ?
mass-spectrometry.  
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Table 2. Natural-product databases that can be used for virtual screening campaigns   
 
Database Number of 
entries  
Additional information Ref 
Super Natural II 355,000 2D structures; vendor information for over 215,000 
compounds 
 ?* 
Universal Natural 
Product Database 
197,201 3D structures assembled from other available 
Chinese databases 
289
 
Chinese Natural 
Product Database 
53,000 Has been used in a virtual screen for PPARJ agonists 290 
Drug Discovery 
Portal 
40,000 Not all natural products, but all based on available 
samples 
49
 
iSMART 20,000 Based on components from traditional Chinese 
medicines 
291, 292
 
Database from 
historical medicinal 
plants, DIOS  
6,702 Successfully used in several virtual screening 
campaigns  
293
 
Marine natural 
products, University 
of California San 
Diego, USA 
2,000 Open source for compounds and for information on 
source organisms and bioactivity information 
 ? ? 
AfroDb 1,000 Compounds from African medicinal plants 
294
 
NuBBE 640 Compounds from Brazilian sources 
295§
 
*http://bioinf-applied.charite.de/supernatural_new/index.php. 
 ?
http://naturalprod.ucsd.edu/. 
§
http://nubbe.iq.unesp.br/portal/nubbedb.html. 2D, two-dimensional; 3D, three-dimensional; 
iSMART, integrated systems biology-associated research with traditional Chinese medicine. 
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Table 3. Natural products in clinical trials for antibiotic activity that represent new chemical classes 
Compound Lead structure 
(chemical 
class) 
Antibiotic 
activity; 
possible 
mechanis
m of 
action 
Original 
natural 
product 
source 
Clinical trial stage*
 
Exeporfiniu
m chloride, 
also known 
as XF-73 
Porphyrin-
based 
photosensitizer 
Gm+ve; 
membran
e 
disruption 
Porphyrin 
derivative 
Phase I study of a nasal gel formulation 
for reduction of staphyloccocal 
infection in otherwise healthy 
volunteers (NCT01592214) 
NVB302 Deoxyactagard
ine B (type B 
lantibiotics) 
Gm+ve; 
inhibition 
of cell-
wall 
synthesis  
Actinoplanes 
liguriae 
Phase I healthy volunteer safety study 
prior to trials in Clostridium difficile 
infections 
(http://www.novactabio.com/news.ph
p) 
POL7080 Protegrin I 
(antimicrobial 
peptide) 
Gm ?ve; 
membran
e-pore 
formation 
Porcine 
leukocytes 
Phase II study for ventilator-associated 
pneumonia linked to Pseudomonas 
aeruginosa infection (NCT02096328) 
LFF571 GE2270A 
(thiopeptide) 
Gm+ve; 
binds to 
bacterial-
elongatio
n factor 
Tu, 
inhibiting 
translatio
n 
Planobispora 
rosea 
Phase II study for moderate Clostridium 
difficile infections (NCT01232595) 
auriclosen
e 
N-
chlorotaurine  
Gm+ve, 
Gm ?ve; 
oxidizing 
agent 
Human 
leukocytes 
Phase II study of an ophthalmic 
solution for bacterial conjunctivitis 
(NCT01877694) 
GSK132232
2 
Actinonin 
(pseudopeptid
e) 
Gm+ve, 
Gm ?ve; 
inhibits 
peptide 
deformyla
se  
Streptomyces 
spp. 
Phase II study for acute bacterial skin 
infection (NCT01209078) 
brilacidin (Cationic 
peptide) 
Gm+ve, 
Gm ?ve; 
membran
e 
disruption 
Based on 
defensins, 
which are 
found in 
many 
vertebrates 
and 
invertebrates  
Phase II  study for serious skin 
infections (NCT02052388) 
LTX-109 (Cationic 
peptide) 
Gm+ve, 
Gm ?ve; 
membran
Synthetic 
peptide, 
based on a 
Phase II study for Gm+ve skin infections 
(NCT01223222) 
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e 
disruption 
pharmacoph
ore identified 
in 
lactoferricin 
B, which was 
derived from 
the 
mammalian 
iron-
chelating 
protein 
lactoferrin  
DPK-060 (Cationic 
peptide) 
Gm+ve, 
Gm ?ve; 
membran
e 
disruption 
Putative 
derivative of 
the 
antibacterial 
domain of 
kininogen 
Phase II study of topical application for 
atopic dermatitis(NCT01522391) 
LL-37 37-residue 
from human 
cathelicidin  
(Cationic 
peptide) 
Gm+ve, 
Gm ?ve; 
membran
e 
disruption 
Human 
cathelicidin 
Phase II trial of a gel formulation for 
venous leg ulcers 
http://www.pergamum.com/blog/perg
amum-announces-final-data-phase-iii-
study-ll-37-patients-chronic-leg-ulcers/ 
*Information modified from REF 8. ClinicalTrials.gov identifier included where possible 
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Glossary  
Chemical space   
The multidimensional space occupied by all chemical compounds. 
 
Pharmacophore 
The spatial arrangement of atoms or groups in a molecule known or predicted to be responsible 
for specific biological activity.  
 
Drug-like 
Sharing certain characteristics  ?  such as size, shape and solubility in water and organic solvents 
 ?  with other molecules that act as drugs. 
 
Log P 
Logarithm of the octanol ?water partition coefficient, which is a measure of a drug's lipophilicity. 
Defined as the ratio of un-ionized drug distributed between the octanol and water phases at 
equilibrium. Higher values imply greater lipophilicity  
 
Cryptic gene clusters 
GĞŶĞƐ ƚŚĂƚ ĂƌĞ ŶŽƌŵĂůůǇ ŶŽƚ ĞǆƉƌĞƐƐĞĚ  ? ‘ƐŝůĞŶƚ ?) and do not translate into a phenotypic 
difference but can become visible in a different environment to generate phenotypic diversity. 
 
Rule of five 
>ŝƉŝŶƐŬŝ ?Ɛ  ?ƌƵůĞ ŽĨ ĨŝǀĞ ? ŝĚĞŶƚŝĨŝĞƐ ƐĞǀĞƌĂů ŬĞǇ ƉƌŽĞƌƚŝĞƐ ƚŚĂƚ ƐŚŽƵůĚ ďĞ ĐŽŶƐŝĚĞƌĞĚ ĨŽƌ
compounds with oral delivery in mind. These properties are molecular mass <500 Da, cLogP <5, 
number of hydrogen-bond donors <5 and number of hydrogen-bond acceptors <10. 
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Stereochemistry 
The spatial arrangement of atoms in a molecule. 
Metabolomics  
The systematic, qualitative and quantitative analysis of all metabolites contained or produced in 
an organism at a specific time and under specific conditions.  
Functional metagenomics  
A method of gene-model validation that can be utilized in the discovery of novel bioactive 
natural products from natural sources.  
 
Metagenomics  
The sequencing and analysis of DNA from environmental samples without the need for 
culturing individual clonal organisms.  
 
 
Dereplication 
The process of using spectroscopic methods to identify known metabolites during the 
preliminary screening stage and eliminating further isolation work on already well-studied 
natural products. 
 
One-Strain ?Many-Compounds  
(OSMaC) An approach to activate metabolic pathways  ?  by altering cultivation parameters, 
through co-cultivation, or through the use of enzyme inhibitors or elicitors  ?  that can be 
combined with genomics scanning.  
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Key points 
 
x Natural products continue to be an important source of leads for new medicines despite 
reduced interest from large pharmaceutical companies 
x Screening collections of natural products can be assembled economically to provide 
excellent coverage of drug-like chemical space and in formats compatible with high-
throughput bioassays 
x Metabolomics enables novel compounds to be identified rapidly in complex mixtures of 
natural products and also provides a means to monitor the production of target molecules 
during fermentations or other production processes 
x Metagenomics and other genetic engineering techniques are enabling target compounds to 
be produced in convenient systems, breaking away from the bottleneck otherwise created 
by difficult to culture microorganisms 
x Examples of recent and current applications of natural products are described for discovery 
of antimicrobials and for inhibitors of protein-protein interactions, particularly as anti-cancer 
agents 
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